UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000001444
Receipt number R000001651
Scientific Title Feasibility study of Capecitabine as adjuvant chemotherapy for stage III colon cancer including RS cancer.
Date of disclosure of the study information 2008/10/22
Last modified on 2017/04/30 18:25:58

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Feasibility study of Capecitabine as adjuvant chemotherapy for stage III colon cancer including RS cancer.

Acronym

Feasibility study of Capecitabine as adjuvant chemotherapy for stage III colon cancer including RS cancer.
(KSCC0803 study)

Scientific Title

Feasibility study of Capecitabine as adjuvant chemotherapy for stage III colon cancer including RS cancer.

Scientific Title:Acronym

Feasibility study of Capecitabine as adjuvant chemotherapy for stage III colon cancer including RS cancer.
(KSCC0803 study)

Region

Japan


Condition

Condition

stage III colon cancer including RS cancer

Classification by specialty

Gastroenterology Hepato-biliary-pancreatic medicine Hematology and clinical oncology
Surgery in general Gastrointestinal surgery

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

The primary objective of this study is to assess the feasibility of capecitabine as adjuvant chemotherapy in Japan.

Basic objectives2

Safety

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase

Phase IV


Assessment

Primary outcomes

the rate of completion of treatment as planned

Key secondary outcomes

Safety
Cumulative incidence of Hand-foot syndrome and hepatic dysfunction
3-years disease free survival rate
5-years disease free survival rate
3-years overall survival rate
5-years overall survival rate


Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

Capecitabine is administrated orally as tablets, 2,500 mg/m2 daily for 14 days followed by a 7-days resting period without treatment, as an intermittent therapy in a 3-weeks cycle for 8 treatment cycles.

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

80 years-old >=

Gender

Male and Female

Key inclusion criteria

1)Histologically confirmed Colorectal adenocarcinoma
2)Histological Stage III Colon,Rectosigmoid
3)Curative resection with D2 or more lymph node dissection
4)Resection of histological curability A was performed
5)age:20-80years old
6)Performance status(ECOG):0or1
7)No prior chemotherapy and radiotherapy
8)Oral intake is possible
9)Sufficient organ functions
10)Chemotherapy will be started within 8 weeks from operation
11)Written informed consent

Key exclusion criteria

1)Pregnant or nursing
2)Medical history of allergy or hypersensitivity reactions to fluoropyrimidines
3)The past of the internal organ transplant
4)Serious coexisting illness
a;severe pulmonary dysfunction
b;ileus or colon dysfunction
c;uncontrolled diabetes mellitus
d;liver cirrhosis
e;uncontrolled hypertension
f;history of myocardial infarction, unstable angina within 6 months prior to the registration
5)Active synchronous or metachronous malignancy other than carcinoma in situ
6)Uncontrollable infectious disease
7)Not suitable for participating in the study for any other reason

Target sample size

92


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Maehara Yoshihiko

Organization

Kyushu University

Division name

Dpt. of surgery and science

Zip code


Address

Maidashi 3-1-1,Higashi-ku,Fukuoka,812-8582

TEL

092-631-2920

Email

kscc2@cres-kyushu.or.jp


Public contact

Name of contact person

1st name
Middle name
Last name KSCC

Organization

CReS Kyushu

Division name

KSCC

Zip code


Address

Maidashi 3-1-1,Higashi-ku,Fukuoka,812-8582

TEL

092-631-2920

Homepage URL


Email

kscc2@cres-kyushu.or.jp


Sponsor or person

Institute

KSCC

Institute

Department

Personal name



Funding Source

Organization

CReS Kyushu

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

九州大学(福岡県)
国立病院機構九州医療センター(福岡県)
国立病院機構九州がんセンター(福岡県)
公立学校共済組合九州中央病院(福岡県)
済生会福岡総合病院(福岡県)
福岡歯科大学医科歯科総合病院(福岡県)
済生会八幡総合病院(福岡県)
産業医科大学(福岡県)
新日鐵八幡記念病院(福岡県)
国立病院機構福岡東医療センター(福岡県)
社会保険田川病院(福岡県)
社会保険仲原病院(福岡県)
久留米大学(福岡県)
久留米大学医療センター(福岡県)
社会保険久留米第一病院(福岡県)
公立八女総合病院(福岡県)
大牟田市立総合病院(福岡県)
麻生飯塚病院(福岡県)
宗像医師会病院(福岡県)
福岡市民病院(福岡県)
済生会唐津病院(佐賀県)
有田共立病院(佐賀県)
健康保険諫早総合病院(長崎県)
佐世保市立総合病院(長崎県)
白十字会 佐世保中央病院(長崎県)
長崎大学(長崎県)
春回会 井上病院(長崎県)
光晴会病院(長崎県)
国立病院機構長崎医療センター(長崎県)
医理会 柿添病院(長崎県)
済生会熊本病院(熊本県)
熊本赤十字病院(熊本県)
熊本大学(熊本県)
健康保険人吉総合病院(熊本県)
大分県立病院(大分県)
大分赤十字病院(大分県)
国立病院機構大分医療センター(大分県)  
国立病院機構別府医療センター(大分県)
大分大学(大分県)
中津市立中津市民病院(大分県)
大分県済生会日田病院(大分県)
小林市立病院(宮崎県)
宮崎県立延岡病院(宮崎県)
社会保険宮崎江南病院(宮崎県)
宮崎県立日南病院(宮崎県)
国立病院機構南九州病院(鹿児島県)
潤愛会 鮫島病院(鹿児島県)
鹿児島大学(鹿児島県)
鹿児島厚生連病院(鹿児島県)
鹿児島共済会南風病院(鹿児島県)
慈愛会 今村病院(鹿児島県)
県民健康プラザ鹿屋医療センター(鹿児島県)
鹿児島県立薩南病院(鹿児島県)
浦添総合病院(沖縄県)
中頭病院(沖縄県)
ハートライフ病院(沖縄県)
琉球大学(沖縄県)
北部地区医師会病院(沖縄県)
広島赤十字・原爆病院(広島県)
松山赤十字病院(愛媛県)
防府消化器病センター 防府胃腸病院(山口県)


Other administrative information

Date of disclosure of the study information

2008 Year 10 Month 22 Day


Related information

URL releasing protocol


Publication of results

Partially published


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2008 Year 07 Month 16 Day

Date of IRB


Anticipated trial start date

2008 Year 07 Month 16 Day

Last follow-up date

2014 Year 09 Month 01 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2008 Year 10 Month 21 Day

Last modified on

2017 Year 04 Month 30 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000001651


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name